Heron Therapeutics HRTX
NASDAQ HRTX
$0.35 -0.01 (-2.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

Heron Therapeutics (HRTX) Return on Sales [ROS] (2010 - 2026)

Updated

Heron Therapeutics (HRTX) recorded Return on Sales [ROS] of -5.43% in Q2 2026, down 1.03 percentage points from -4.40% a year earlier but up 8.30 percentage points from the prior quarter.

Analysis

Heron Therapeutics (HRTX) Return on Sales [ROS] (2010 - 2026) Analysis & Trends

On a TTM basis, Heron Therapeutics' Return on Sales [ROS] came in at -7.19% as of Jun 30, 2026, down 8.01 percentage points year-over-year; for FY2025, it was -1.64%, up 6.35 percentage points from FY2024.

  • Annual Return on Sales [ROS] has increased for five straight years, with a five-year change of +255.77 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -7.99% in FY2024 (+79.08 pp), -87.07% in FY2023 (+75.14 pp), -162.21% in FY2022 (+90.06 pp) and -252.27% in FY2021 (+5.14 pp).
  • Quarterly Return on Sales [ROS] has ranged from -268.25% in Q1 2022 to 10.23% in Q4 2024 over the past five years.
  • On a year-over-year basis, Return on Sales [ROS] has declined for three consecutive quarters, with an average year-over-year change of +13.89 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 191.41 percentage points in Q4 2022, against a drop of 21.83 percentage points in Q1 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at -13.73% (Q1 2026), 0.09% (Q4 2025) and -10.71% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Heron Therapeutics 66.45 Mn -123.12 Mn 26.09 Mn -5.43%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -5.43%
Mar 31, 2026 -13.73%
Dec 31, 2025 0.09%
Sep 30, 2025 -10.71%
Jun 30, 2025 -4.40%
Mar 31, 2025 8.11%
Dec 31, 2024 10.23%
Sep 30, 2024 -13.59%
Jun 30, 2024 -17.89%
Mar 31, 2024 -13.84%
Dec 31, 2023 -29.85%
Sep 30, 2023 -79.31%
Jun 30, 2023 -133.50%
Mar 31, 2023 -111.64%
Dec 31, 2022 -67.79%
Sep 30, 2022 -157.71%
Jun 30, 2022 -179.15%
Mar 31, 2022 -268.25%
Dec 31, 2021 -259.20%
Sep 30, 2021 -222.59%
API Access

Heron Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=HRTX&period=max&api_key=YOUR_API_KEY